Monitoring Agency Report for the half year ended March 31, 2025
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has filed the Monitoring Agency Report from Brickwork Ratings India for the half year ended March 31, 2025. The company raised ₹117.02 crore through a Preferential Issue of Equity Shares and Compulsorily Convertible Debentures (CCDs) in November 2024, with ₹117.01 crore actually received. As on March 31, 2025, the company has utilized about ₹10.96 crore, including ₹3.60 crore for facility upgradation of its subsidiaries (Adley Formulations and Adley Lab), ₹0.95 crore for new R&D setup, ₹0.63 crore for manufacturing capex, and ₹5.78 crore for general corporate purposes (which included a ₹3.27 crore payment to O3 Capital Global Advisory for issue advisory). The remaining ~₹106 crore of unutilized funds are parked in fixed deposits with HDFC and ICICI Banks, earning returns between 6.5% and 7.71%. The report confirms no deviation from disclosed objects of the issue, all statutory approvals are in place, and no unfavorable events affecting viability have been flagged.
This is a routine regulatory compliance filing with a clean report — no deviation from stated use of funds. Reassuringly, the unutilized money is earning interest in fixed deposits, but the relatively slow deployment (only ~9% utilized in ~4 months) on big-ticket items like manufacturing capex (₹44 crore) and capital investments (₹20 crore) is worth watching. Overall neutral for shareholders.